Kornitzer Capital Management Inc. KS Reduces Holdings in Insulet Corporation $PODD

Kornitzer Capital Management Inc. KS trimmed its stake in shares of Insulet Corporation (NASDAQ:PODD) by 17.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,300 shares of the medical instruments supplier’s stock after selling 3,200 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Insulet were worth $3,211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. State Street Corp boosted its stake in shares of Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after purchasing an additional 65,317 shares during the period. Geode Capital Management LLC grew its holdings in shares of Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares during the last quarter. Invesco Ltd. increased its stake in shares of Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after buying an additional 141,167 shares during the period. Norges Bank purchased a new position in shares of Insulet in the fourth quarter worth $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Insulet by 3.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after buying an additional 29,690 shares during the last quarter.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.36% of the company’s stock.

Insulet Stock Up 1.9%

Shares of PODD stock traded up $2.99 during midday trading on Friday, reaching $161.28. 723,321 shares of the stock were exchanged, compared to its average volume of 1,357,711. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The firm has a market cap of $11.17 billion, a PE ratio of 37.51, a price-to-earnings-growth ratio of 1.12 and a beta of 1.11. The company’s 50 day moving average is $152.93 and its two-hundred day moving average is $211.33. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the business posted $1.02 EPS. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts predict that Insulet Corporation will post 6.46 EPS for the current year.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Stifel kept a buy rating on PODD, although it lowered its price target from $250 to $225, suggesting the stock still has meaningful upside despite recent volatility. Benzinga reference
• Neutral Sentiment: Insulet also appeared in a positive-style growth note and an article discussing the stock’s valuation after a sharp decline, but these pieces did not provide fresh company-specific catalysts. Yahoo Finance reference
• Neutral Sentiment: Short-interest data showed no reported short interest as of July 10, so it does not currently signal a meaningful bearish positioning change.
• Negative Sentiment: Several law firms announced or promoted class-action lawsuits against Insulet over alleged securities fraud and Omnipod safety disclosures, which can create investor uncertainty and pressure the stock. PR Newswire reference

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PODD. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Wells Fargo & Company decreased their price objective on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. BTIG Research lowered their price objective on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, May 26th. Wall Street Zen lowered shares of Insulet from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 target price on shares of Insulet in a research note on Wednesday, May 27th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $237.08.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.